ArticleHormones & cancer2018
Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.
Article in Hormones & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study.Breast cancer (Tokyo, Japan) · 2025Article
- Molecule subtypes play important roles for second primary malignancies development based on 324,661 breast cancer survivors.Scientific reports · 2025Article
- Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.Therapeutic advances in medical oncology · 2025Review
- Variation in patterns of second primary malignancies across U.S. race and ethnicity groups: a Surveillance, Epidemiology, and End Results (SEER) analysis.Cancer causes & control : CCC · 2024Article
- Causal effect analysis of estrogen receptor associated breast cancer and clear cell ovarian cancer.American journal of translational research · 2024Article
- Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.Breast cancer (Tokyo, Japan) · 2023Article
- Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.Cancer research · 2022Article
- Risk and Survival of Third Primary Cancers in a Population-Based Cohort of Breast Cancer Patients.Breast care (Basel, Switzerland) · 2022Article
- Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.Frontiers in oncology · 2022Review
- Survival outcomes in prostate cancer patients with a prior cancer.Translational andrology and urology · 2021Article
- Tamoxifen and Endometrial Cancer: A Janus-Headed Drug.Cancers · 2020Review
- Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study.Archives of gynecology and obstetrics · 2020Article
- RAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells.Archives of clinical toxicology · 2020Article
- The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study.Journal of Cancer · 2020Article
- Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.International journal of clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer survivors are at an increased risk of second primary cancers, and the risk factors for the latter may have clinical significance. The aims of our study were to evaluate the incidences and risk factors of second primary female genital cancers (corpus uteri, cervix uteri plus ovary) in a large cohort of breast cancer survivors. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined the standardized incidence ratio (SIR) and risk factors for second primary female genital cancers observed between 2000 and 2014. Breast cancer survivors had increased SIRs for second corpus uteri cancers and second ovarian cancers and a decreased SIR for second cervical cancers (SIR 1.17, 1.12, and 0.64, respectively). Risk factors of second corpus uteri cancers were the age at first cancer diagnosis, race (black vs. white, aHR = 1.142 95% CI 1.005-1.298), and progesterone receptor (PR) status (PR+ vs. PR-, aHR = 1.131 95% CI 1.004-1.273). In addition, the risk of second ovarian cancer was positively associated with age while inversely associated with race (black vs. white, aHR = 0.691 95% CI 0.555-0.859) and estrogen receptor (ER) status (ER+ vs. ER-, aHR = 0.655 95% CI 0.544-0.788). Age, race, and hormone receptor status are risk factors of developing second female genital cancers among breast cancer survivors. Older age, black race, and a PR+ status in survivors are associated with a higher risk of second corpus uteri cancers. Additionally, older age and an ER- status should increase vigilance for potential second ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.